CDK2 and prostate cancer: In prostate cancer, CDK2 overexpression is associated with recurrence risk, and its expression is more than double in metastases compared to primary tumors.312 Glioma tumors display high dependence on CDK2, with increased expression potentially due to copy number alterations, altered methylation, or enhanced transcriptional activation.